ClinicalTrials.gg
CompletedNCT02985398PREVAILUpdated Apr 21, 2020Results posted

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

A Phase 3 interventional study of ALD403 (Eptinezumab) in Migraine Disorder, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
15th of 21
128 · median 193
Started
2016
with 1 other
Phase 3
13 of 21
5 open now
Registered
6th of 21
by date
Lead sponsor
6 of 21
Alder Biopharmaceuticals, Inc.

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 15th largest by enrollment, is one of 2 that started in 2016, is one of 13 in phase 3, and was the 6th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine

03

Conditions studied

  • Migraine Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.

Exclusion criteria

Exclusion Criteria:

  • Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.
  • Confounding and pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    ALD403 (Eptinezumab) Dose Level 1

    ALD403 (Eptinezumab) Dose Level 1 (IV)

    Biological: ALD403 (Eptinezumab)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)

    Treatment emergent adverse events were defined as adverse events with start date and time on or after the date and time of the initial study drug infusion.

    Time frame: 104 Weeks

  2. Number of Participants With a Clinically Significant Electrocardiogram

    Overall investigator interpretation of participant electrocardiogram

    Time frame: Baseline, Day 0 Postdose, Week 12, 24, 36, 48 60, 72 and 84 (Predose and Postdose), and Week 104

  3. Number of Participants With Any Clinically Significant Laboratory Values

    Each of the laboratory values that were reported as abnormal and clinically significant and entered as adverse events in the database.

    Time frame: 104 Weeks

  4. Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior on Columbia-Suicide Severity Rating Scale (C-SSRS)

    Baseline responses are collected at screening and assess suicidal ideation in the past 6 months. Post baseline reports the worst assessment of suicidal ideation since the last visit for all post baseline visits.

    Time frame: 104 Weeks

  5. Number of Participants With Any Clinically Significant (CS) Changes in Vital Signs

    Changes in vital signs that were considered clinically meaningful or clinically significant (CS) by the Investigator

    Time frame: 104 Weeks

Secondary outcomes

  1. Patient Global Impression of Change (PGIC) at Week 104

    The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

    Time frame: Week 104

  2. Change in Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores

    The SF-36 is a health survey consisting of 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (scale range: 0=worst to 100=best). Increases from baseline indicate improvement.

    Time frame: Baseline to Week 12

  3. Health Related Quality of Life (EQ-5D-5L) at Week 12

    The EQ-5D-5L is a descriptive health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

    Time frame: Week 12

  4. Change in Baseline of Headache Impact Test (HIT-6) Score

    The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assess over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). The change in baseline will be calculated from the average scores.

    Time frame: Baseline, Week 1-4, Week 9-12

  5. Change in Most Bothersome Symptom at Week 48

    The Investigator verbally obtained the most bothersome symptom associated with the participant's migraine during the screening visit. The most bothersome symptom may include nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, or other migraine related symptoms. Participants were asked to rate the improvement in this symptom from screening on a seven-point scale.

    Time frame: Baseline to Week 48

  6. Change From Baseline of Migraine Disability Assessment (MIDAS) Total Score

    The MIDAS questionnaire measures the effect headaches have on the participant's daily functioning. MIDAS is composed of five questions that ask about the participant's performance over the past 3 months. The response to each question is provided in number of days which are summed to determine the MIDAS total score and level of disability: 0-5, MIDAS Grade I, little or no disability; 6-10, MIDAS Grade II, mild disability; 11-20, MIDAS Grade III, moderate disability; 21+, MIDAS Grade IV, severe disability; A higher value represents a worse outcome.

    Time frame: Baseline to Week 12

  7. Development of Anti-ALD403 Antibody by Visit

    Serum blood samples were taken at visits to test for the development of antibodies to ALD403, or anti-drug antibodies (ADA). Participants who tested positive for anti-ALD403 antibodies at the time of the last study visit were asked to provide up to 2 additional blood samples for immunogenicity testing at approximately 3 month intervals for up to 6 months.

    Time frame: Baseline, Week 2, 4, 8, 12, 24, 36, 48, 72 and 104

  8. Summary of Neutralizing Properties of Anti-ALD403 Antibodies by Visit

    Any samples that were positive for anti-ALD403 antibody, there was additional testing to characterize the anti-ALD403 antibody for the potential to neutralize (NAb) ALD403 activity.

    Time frame: Baseline, Week 2, 4, 8, 12, 24, 36, 48, 72 and 104

07

Results

Posted Apr 21, 2020

Participant flow

Participant flow — Overall Study
Milestone300 mg ALD403
Started128
Participants treated128
Completed106
Not completed22
Withdrew: Adverse event1
Withdrew: Lost to follow-up4
Withdrew: Withdrawal by subject8
Withdrew: Study burden9

Outcome measures

PrimaryNumber of Participants With Any Treatment Emergent Adverse Events (TEAEs)

Treatment emergent adverse events were defined as adverse events with start date and time on or after the date and time of the initial study drug infusion.

Time frame:
104 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
Participants300 mg ALD403
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)91
PrimaryNumber of Participants With a Clinically Significant Electrocardiogram

Overall investigator interpretation of participant electrocardiogram

Time frame:
Baseline, Day 0 Postdose, Week 12, 24, 36, 48 60, 72 and 84 (Predose and Postdose), and Week 104
Reported as:
Count of participants · Participants
Number of Participants With a Clinically Significant Electrocardiogram
Participants300 mg ALD403
Baseline0
Day 0 Postdose1
Week 12 Predose0
Week 12 Postdose0
Week 24 Predose0
Week 24 Postdose0
Week 36 Predose0
Week 36 Postdose0
Week 48 Predose0
Week 48 Postdose0
Week 60 Predose1
Week 60 Postdose1
Week 72 Predose1
Week 72 Postdose1
Week 84 Predose1
Week 84 Postdose0
Week 1041
PrimaryNumber of Participants With Any Clinically Significant Laboratory Values

Each of the laboratory values that were reported as abnormal and clinically significant and entered as adverse events in the database.

Time frame:
104 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Clinically Significant Laboratory Values
Participants300 mg ALD403
Hematocrit Decreased1
Hemoglobin Decreased1
Blood Glucose Increased1
Hypertriglyceridemia1
Blood Potassium Decreased1
Hypokalemia1
Blood Mercury Abnormal1
Hypercholesterolemia1
Hyperlipidemia1
PrimaryNumber of Participants Experiencing Suicidal Ideation or Suicidal Behavior on Columbia-Suicide Severity Rating Scale (C-SSRS)

Baseline responses are collected at screening and assess suicidal ideation in the past 6 months. Post baseline reports the worst assessment of suicidal ideation since the last visit for all post baseline visits.

Time frame:
104 Weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior on Columbia-Suicide Severity Rating Scale (C-SSRS)
Participants300 mg ALD403
Participants Experiencing Suicidal Ideation0
Participants Experiencing Suicidal Behavior0
PrimaryNumber of Participants With Any Clinically Significant (CS) Changes in Vital Signs

Changes in vital signs that were considered clinically meaningful or clinically significant (CS) by the Investigator

Time frame:
104 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Clinically Significant (CS) Changes in Vital Signs
Participants300 mg ALD403
Number of CS changes in diastolic blood pressure0
Number of CS changes in systolic blood pressure0
Number of CS changes in heart rate value0
SecondaryPatient Global Impression of Change (PGIC) at Week 104

The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

Time frame:
Week 104
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) at Week 104
Participants300 mg ALD403
Very Much Improved47
Much Improved33
Minimally Improved11
No Change5
Minimally Worse0
Much Worse0
Very Much Worse0
SecondaryChange in Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores

The SF-36 is a health survey consisting of 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (scale range: 0=worst to 100=best). Increases from baseline indicate improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change in Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores
score on a scale300 mg ALD403
Bodily Pain5.8 ± 10.06
General Health1.6 ± 6.46
Mental Component1.9 ± 7.89
Mental Health1.4 ± 7.86
Physical Component4.5 ± 7.08
Physical Functioning2.9 ± 6.15
Role Emotional2.3 ± 9.09
Role Physical4.8 ± 8.34
Social Functioning4.9 ± 9.13
Vitality3.0 ± 7.90
SecondaryHealth Related Quality of Life (EQ-5D-5L) at Week 12

The EQ-5D-5L is a descriptive health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Health Related Quality of Life (EQ-5D-5L) at Week 12
Participants300 mg ALD403
Mobility — No problems110
Mobility — Slight problems11
Mobility — Moderate problems3
Mobility — Severe problems0
Mobility — Extreme problems0
Self-care — No problems121
Self-care — Slight problems3
Self-care — Moderate problems0
Self-care — Severe problems0
Self-care — Extreme problems0
Usual Activities — No problems95
Usual Activities — Slight problems18
Usual Activities — Moderate problems11
Usual Activities — Severe problems0
Usual Activities — Extreme problems0
Pain/Discomfort — No problems55
Pain/Discomfort — Slight problems42
Pain/Discomfort — Moderate problems22
Pain/Discomfort — Severe problems5
Pain/Discomfort — Extreme problems0
Anxiety/Depression — No problems96
Anxiety/Depression — Slight problems22
Anxiety/Depression — Moderate problems6
Anxiety/Depression — Severe problems0
Anxiety/Depression — Extreme problems0
SecondaryChange in Baseline of Headache Impact Test (HIT-6) Score

The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assess over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). The change in baseline will be calculated from the average scores.

Time frame:
Baseline, Week 1-4, Week 9-12
Reported as:
Mean · score on a scale
Change in Baseline of Headache Impact Test (HIT-6) Score
score on a scale300 mg ALD403
Week 1-4-8.0 ± 8.06
Week 9-12-7.9 ± 7.96
SecondaryChange in Most Bothersome Symptom at Week 48

The Investigator verbally obtained the most bothersome symptom associated with the participant's migraine during the screening visit. The most bothersome symptom may include nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, or other migraine related symptoms. Participants were asked to rate the improvement in this symptom from screening on a seven-point scale.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Change in Most Bothersome Symptom at Week 48
Participants300 mg ALD403
Very Much Improved40
Much Improved44
Minimally Improved17
No Change11
Minimally Worse0
Much Worse0
Very Much Worse0
SecondaryChange From Baseline of Migraine Disability Assessment (MIDAS) Total Score

The MIDAS questionnaire measures the effect headaches have on the participant's daily functioning. MIDAS is composed of five questions that ask about the participant's performance over the past 3 months. The response to each question is provided in number of days which are summed to determine the MIDAS total score and level of disability: 0-5, MIDAS Grade I, little or no disability; 6-10, MIDAS Grade II, mild disability; 11-20, MIDAS Grade III, moderate disability; 21+, MIDAS Grade IV, severe disability; A higher value represents a worse outcome.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change From Baseline of Migraine Disability Assessment (MIDAS) Total Score
score on a scale300 mg ALD403
Change From Baseline of Migraine Disability Assessment (MIDAS) Total Score-36.3 ± 51.85
SecondaryDevelopment of Anti-ALD403 Antibody by Visit

Serum blood samples were taken at visits to test for the development of antibodies to ALD403, or anti-drug antibodies (ADA). Participants who tested positive for anti-ALD403 antibodies at the time of the last study visit were asked to provide up to 2 additional blood samples for immunogenicity testing at approximately 3 month intervals for up to 6 months.

Time frame:
Baseline, Week 2, 4, 8, 12, 24, 36, 48, 72 and 104
Reported as:
Count of participants · Participants
Development of Anti-ALD403 Antibody by Visit
Participants300 mg ALD403
Day 0: ADA Results — ADA Positive0
Day 0: ADA Results — ADA Negative128
Week 2 : ADA Results — ADA Positive1
Week 2 : ADA Results — ADA Negative126
Week 4 : ADA Results — ADA Positive0
Week 4 : ADA Results — ADA Negative126
Week 8 : ADA Results — ADA Positive7
Week 8 : ADA Results — ADA Negative118
Week 12 : ADA Results — ADA Positive11
Week 12 : ADA Results — ADA Negative112
Week 24 : ADA Results — ADA Positive21
Week 24 : ADA Results — ADA Negative99
Week 36 : ADA Results — ADA Positive9
Week 36 : ADA Results — ADA Negative109
Week 48 : ADA Results — ADA Positive6
Week 48 : ADA Results — ADA Negative107
Week 72 : ADA Results — ADA Positive4
Week 72 : ADA Results — ADA Negative97
Week 104 : ADA Results — ADA Positive0
Week 104 : ADA Results — ADA Negative96
SecondarySummary of Neutralizing Properties of Anti-ALD403 Antibodies by Visit

Any samples that were positive for anti-ALD403 antibody, there was additional testing to characterize the anti-ALD403 antibody for the potential to neutralize (NAb) ALD403 activity.

Time frame:
Baseline, Week 2, 4, 8, 12, 24, 36, 48, 72 and 104
Reported as:
Count of participants · Participants
Summary of Neutralizing Properties of Anti-ALD403 Antibodies by Visit
Participants300 mg ALD403
Day 0: NAb Results — NAb Positive0
Day 0: NAb Results — NAb Negative0
Week 2 : NAb Results — NAb Positive0
Week 2 : NAb Results — NAb Negative1
Week 4 : NAb Results — NAb Positive0
Week 4 : NAb Results — NAb Negative0
Week 8 : NAb Results — NAb Positive3
Week 8 : NAb Results — NAb Negative4
Week 12 : NAb Results — NAb Positive8
Week 12 : NAb Results — NAb Negative3
Week 24 : NAb Results — NAb Positive5
Week 24 : NAb Results — NAb Negative16
Week 36 : NAb Results — NAb Positive1
Week 36 : NAb Results — NAb Negative8
Week 48 : NAb Results — NAb Positive1
Week 48 : NAb Results — NAb Negative5
Week 72 : NAb Results — NAb Positive0
Week 72 : NAb Results — NAb Negative4
Week 104 : NAb Results — NAb Positive0
Week 104 : NAb Results — NAb Negative0

Adverse events

Collected over Baseline to Week 104 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
300 mg ALD4030/128 (0%)5/128 (3.9%)49/128 (38.3%)
Most frequent serious events
Most frequent serious events
Event300 mg ALD403
Anaphylactic ReactionImmune system disorders1/128
PneumoniaInfections and infestations1/128
Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders1/128
OsteoarthritisMusculoskeletal and connective tissue disorders1/128
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/128
Conversion DisorderPsychiatric disorders1/128
Most frequent other events
Most frequent other events
Event300 mg ALD403
NasopharyngitisInfections and infestations18/128
SinusitisInfections and infestations10/128
Upper respiratory tract infectionInfections and infestations10/128
InfluenzaInfections and infestations8/128
BronchitisInfections and infestations7/128
MigraineNervous system disorders7/128

Baseline characteristics

Safety Population includes all participants who received study drug.

Age, Continuous
Age, Continuous(years)300 mg ALD403
Mean41.5 ± 11.33
Sex: Female, Male
Sex: Female, Male(Participants)300 mg ALD403
Female109
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)300 mg ALD403
Hispanic or Latino26
Not Hispanic or Latino102
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)300 mg ALD403
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White122
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)300 mg ALD403
United States128
Duration of migraine diagnosis at baseline
Duration of migraine diagnosis at baseline(years)300 mg ALD403
Mean21.2 ± 11.65
08

Study locations

20 sites
  • Research Site
    San Diego, California 92108, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Colorado Springs, Colorado 80918, United States
  • Research Site
    Bradenton, Florida 34201, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Massachusetts
    Miami, Florida 33125, United States
  • Research Site
    Tampa, Florida 33634, United States
  • Research Site
    Winter Haven, Florida 33880, United States
  • Research Site
    Prairie Village, Kansas 66206, United States
  • Massachusetts
    Boston, Massachusetts 02131, United States
  • Research Site
    North Attleboro, Massachusetts 02760, United States
  • 02481
    Wellesley, Massachusetts 02481, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    Brooklyn, New York 11229, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    Dayton, Ohio 45432, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Chattanooga, Tennessee 37421, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Bellevue, Washington 98007, United States
09

References and documents

Publications

  • Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol. 2022 Jul 8;22(1):251. doi: 10.1186/s12883-022-02774-3. PubMed 35804294 ↗
  • Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5. Erratum In: J Headache Pain. 2021 May 25;22(1):46. doi: 10.1186/s10194-021-01253-3. PubMed 33781209 ↗
  • Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021 Mar 19;21(1):126. doi: 10.1186/s12883-021-02123-w. PubMed 33740902 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2018, 16 months.

Results were first posted in Apr 2020, 2 years after primary completion. A results delay was requested in May 2019.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2016
First posted
Dec 7, 2016
StartActual
Dec 2016
Primary completionActual
Apr 2018
CompletionActual
Mar 2019
Results delay requested
May 1, 2019
Results first posted
Apr 21, 2020
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02985398
Responsible party
Sponsor
First posted
Dec 7, 2016
Start date
Dec 2016
Primary completion
Apr 2018
Completion
Mar 2019
Results posted
Apr 21, 2020
Last update
Apr 21, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion